On June 13, 2022 Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, reported it will present positive data on its lead investigational drug, Rhenium-186 NanoLiposome (186RNL), from the Phase 1/2a ReSPECT-GBM dose escalation clinical trial in patients with recurrent glioblastoma (GBM) during an oral presentation at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2022 Annual Meeting, on June 14 at 10:20 AM PT in Vancouver, British Columbia, Canada (Press release, Cytori Therapeutics, JUN 13, 2022, View Source [SID1234615931]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
According to the interim data, 186RNL delivered via convection enhanced delivery (CED) provides direct therapy with high radiation absorbed doses for local tumor control with minimal brain and whole-body radiation exposure. 186RNL’s tumor-killing effects were observed when greater than 100 Gy doses are delivered to greater than 80% of a tumor without dose-limiting toxicity.
The presentation, titled "Rhenium-186-NanoLiposome (186RNL) in the treatment of relapse/recurrent glioblastoma (rGBM): a novel approach to cancer therapy," outlines data from the ReSPECT-GBM trial, substantially funded by the U.S. National Institutes of Health/National Cancer Institute, which has thus far evaluated 24 adult patients with recurrent GBM across seven cohorts of increasing dose. To date, there have been no significant adverse events during the dose escalation.
"186RNL’s novel localized radio-nanotherapeutic approach has significant potential to translate into treatment for a broad range of tumors where local tumor control is difficult or all other therapies are exhausted, ineffective or toxic," said William Phillips, M.D., Nuclear Medicine Physician at UT Health-San Antonio, and primary presenter. "To treat glioblastoma, the targeted and controlled use of 186RNL is critical for patients as we aim to mitigate brain and whole-body exposure. The novel administration via localized radio-nanotherapeutic enables high doses of radiation to be absorbed while protecting patients from the harsh effects of unnecessary radiation exposure."
The Company expects to initiate a Phase 2/registrational trial of 186RNL in patients with recurrent GBM by the end of 2022. In addition, the Company is continuing to evaluate 186RNL in leptomeningeal metastases as part of the ReSPECT-LM Phase 1/2a dose escalation clinical trial and is in late-stage planning for the treatment of pediatric ependymoma and high-grade GBM.
Upcoming Company Presentation at BIO International Convention
Additionally, Russ Havranek, Vice President of Corporate Strategy and New Product Planning of Plus Therapeutics will present a corporate update in person at the BIO International Convention 2022 on June 15 at 10:30 AM PT in San Diego, California.
Copies of both presentations will be made available under the Presentations tab of the For Investors section of the Company’s website following the meetings at www.plustherapeutics.com.